Core Viewpoint - Baosai Technology-B (02315) has seen a significant stock price increase, with a recent rise of over 10%, attributed to strong earnings forecasts and strategic partnerships in the biopharmaceutical sector [1] Group 1: Earnings Forecast - The company has projected a net profit attributable to shareholders for 2025 between 162 million to 182 million yuan, representing a year-on-year increase of 384.26% to 443.88% [1] - The growth is driven by the continuous expansion in overseas markets and a recovery in the domestic biopharmaceutical industry, leading to rapid revenue growth [1] Group 2: Operational Efficiency - High technical barriers have ensured that the company's gross profit margin remains elevated, while lean management initiatives have further enhanced operational efficiency [1] - The company's profitability has improved rapidly as a result of these factors [1] Group 3: Strategic Partnerships - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, which are expected to contribute to revenue through milestone payments [1] - Notable partnerships include a global licensing agreement with BeiGene for antibody molecules and an agreement with Merck for the development of antibody-conjugated LNPs using the RenMice platform [1]

3、港股通5日占比增持榜（前10名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 钧达股份(02865) | +12.94% | 62.00% | | 南华期货股份(02691) | +9.45% | 11.03% | | 山东墨龙(00568) | +3.83% | 61.06% | | 君实生物(01877) | +3.41% | 56.39% | | 百奥赛图-B(02315) | +3.25% | 23.55% | | 中伟新材(02579) | +2.87% | 16.58% | | 长飞光纤光缆(06869) | +2.50% | 57.18% | | 南方东西精选(03441) | +2.33% | 16.05% | | 新意网集团(01686) | +2.26% | 7.24% | | 方舟健客(06086) | +1.96% | 6.24% | 智通财经APP获悉，根据2026年1月30日披露数据，山东墨龙（00568）、钧达股份（02865）、京城机 电股份（00187）港股通持股占比增加值最大，分别增加2.80%、2.32%、1.51% ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook with expected stock price appreciation of over 15% relative to the benchmark index [2][11]. Core Insights - The company is projected to achieve significant revenue growth driven by its core business and antibody platform, with expected revenues of RMB 1.376 billion in 2025, representing a year-on-year growth of 40.4% [2][8]. - The net profit attributable to shareholders is forecasted to reach RMB 167 million in 2025, reflecting a staggering growth rate of 399.3% compared to the previous year [2][8]. - The company has made substantial advancements in its animal model and preclinical CRO business, which are key drivers of revenue growth, particularly in the first half of 2025 [8]. Financial Forecasts - Revenue projections for 2024, 2025, 2026, and 2027 are RMB 980 million, RMB 1.376 billion, RMB 1.845 billion, and RMB 2.416 billion, respectively, with growth rates of 36.8%, 40.4%, 34.1%, and 31.0% [2][9]. - The net profit attributable to shareholders is expected to grow from RMB 34 million in 2024 to RMB 530 million in 2027, with corresponding growth rates of 108.8%, 399.3%, 93.3%, and 63.6% [2][9]. - Earnings per share (EPS) are projected to increase from RMB 0.08 in 2024 to RMB 1.19 in 2027, indicating strong profitability growth [2][9]. Business Developments - The company has successfully expanded its humanized mouse model offerings, launching over 400 new models in 2025, which enhances its technological barriers and supports its goal of becoming a global hub for new drug development [8]. - Strategic partnerships have been established with leading pharmaceutical companies, including a global licensing agreement with BeiGene and an antibody licensing deal with Merck, which are expected to contribute to long-term revenue growth [8].

Core Viewpoint - The company Baidu Biotechnology (02315) has announced a positive earnings forecast for the fiscal year 2025, leading to a significant increase in its stock price by nearly 13% following the announcement [1] Financial Performance - The company expects to achieve revenue of approximately 1.369 billion to 1.389 billion yuan, representing an increase of 389 million to 408 million yuan compared to the previous year, with a year-on-year growth rate of 39.61% to 41.65% [1] - The anticipated net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, which is an increase of 129 million to 149 million yuan from the previous year, indicating a substantial year-on-year growth of 384.26% to 443.88% [1] Market Dynamics - The company's revenue growth is attributed to the continuous expansion in overseas markets, coupled with a recovery in the domestic biopharmaceutical industry [1] - The high barriers to entry in technology have helped maintain high gross margins, while lean management initiatives have further enhanced operational efficiency, leading to a rapid increase in profitability [1]

（原标题：港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%） 智通财经APP获悉，百奥赛图-B(02315)盈喜后涨近13%，截至发稿，涨8.82%，报47.88港元，成交额 2771.5万港元。 公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长；高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 消息面上，百奥赛图发布2025年度业绩预告，预计全年实现营收约13.69亿元-13.89亿元，较上年同期增 加3.89亿元至4.08亿元，同比增幅为39.61%到41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，较 上年同期增加1.29亿元至1.49亿元，同比大幅增长384.26%至443.88%。 ...

公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长；高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 百奥赛图-B(02315)盈喜后涨近13%，截至发稿，涨8.82%，报47.88港元，成交额2771.5万港元。 消息面上，百奥赛图发布2025年度业绩预告，预计全年实现营收约13.69亿元-13.89亿元，较上年同期增 加3.89亿元至4.08亿元，同比增幅为39.61%到41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，较 上年同期增加1.29亿元至1.49亿元，同比大幅增长384.26%至443.88%。 ...

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Nanhua Futures (02691) saw the largest increase in holdings, up by 4.45% to a total of 10.44% [2]. - Junshi Biosciences (01877) experienced a 2.39% increase, bringing its total holding to 55.84% [2]. - Lion Group (02562) had a 2.21% increase, resulting in a holding of 53.31% [2]. - Other notable increases include Haotian International Investment (01341) at +1.61% (67.02%) and Junda Co., Ltd. (02865) at +1.43% (59.68%) [2]. Group 2: Companies with Decreased Holdings - Yihua Tong (02402) reported the largest decrease, down by 2.06% to 28.06% [2]. - Shandong Molong (00568) saw a reduction of 1.99%, with a current holding of 58.26% [2]. - Jihong Co., Ltd. (02603) decreased by 1.27%, now holding 57.37% [2]. - Other significant decreases include China Merchants Hengsheng Technology (03423) at -0.85% (3.15%) and CIFI Holdings Group (00884) at -0.82% (9.03%) [2]. Group 3: Five-Day Changes in Holdings - Junda Co., Ltd. (02865) had the highest five-day increase at +12.13%, reaching 59.68% [3]. - Nanhua Futures (02691) increased by 9.08% to 10.44% [3]. - Other notable increases include Baidu Biotechnology-B (02315) at +3.13% (22.65%) and Junshi Biosciences (01877) at +2.77% (55.84%) [3]. Group 4: Twenty-Day Changes in Holdings - Junda Co., Ltd. (02865) also led the twenty-day increase with +27.85%, holding 59.68% [4]. - Baidu Biotechnology-B (02315) increased by +14.85% to 22.65% [4]. - Other significant increases include Zhongwei New Materials (02579) at +11.72% (16.27%) and Youjia Innovation (02431) at +8.62% (14.46%) [4].

1月29日，诺诚健华和百奥赛图发布2025年业绩预告。 诺诚健华扭亏为盈 诺诚健华预计全年实现营业收入23.65亿元左右，与上年同期相比增长134%左右；全年实现归属于母公司 所有者的净利润为6.33亿元左右，与上年同期相比增加10.74亿元左右；全年实现归属于母公司所有者扣 除非经常性损益后净利润为5.34亿元，与上年同期相比增加9.74亿元左右。 诺诚健华表示，2025年业绩变化的主要原因在于： 1） 药品收入持续快速增长。 2025年4月，奥布替尼获批新适应症，用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 （CLL/SLL）成人患者。此前，奥布替尼有三项获批适应症：既往至少接受过一种治疗的成人复发难治 CLL/SLL患者，既往至少接受过一种治疗的成人复发难治套细胞淋巴瘤（MCL）患者及既往至少接受过 一种治疗的成人复发难治边缘区淋巴瘤（MZL）患者，均纳入国家医保药品目录。 奥布替尼为中国首个且唯一获批针对MZL适应症的BTK抑制剂。除奥布替尼外，2025年5月，坦昔妥单抗 联合来那度胺治疗不适合ASCT条件的复发难治弥漫性大B细胞淋巴瘤（DLBCL）成人患者的上市申请获 得NMPA批淮。综合以上影 ...

证券日报网讯 1月29日，百奥赛图发布2025年年度业绩预盈公告称，公司预计2025年年度归属于母公司 所有者的净利润16，242.86万元到18，242.86万元，与上年同期相比，将增加12，888.68万元到14， 888.68万元，同比增加384.26%到443.88%。 （文章来源：证券日报） ...

智通财经APP讯，百奥赛图-B(02315)发布2025年度业绩预告，经公司财务部门初步测算，预计本集团 2025年年度实现营业收入人民币13.69亿元至人民币13.89亿元，与上年同期相比，将增加人民币3.88亿 元至人民币4.08亿元，同比增加39.61%至41.65%。预计本集团2025年年度实现归属于母公司所有者的净 利润人民币1.62亿元至人民币1.82亿元，与上年同期相比，将增加人民币1.29亿元到人民币1.49亿元，同 比增加384.26%到443.88%。预计本集团2025年年度实现归属于母公司所有者的扣除非经常性损益的净 利润人民币1.05亿元到人民币1.25亿元，与上年同期相比，将增加人民币8195.13万元到人民币1.02亿 元，同比增加356.81%到443.88%。 公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长。高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 ...